| Literature DB >> 31034197 |
Ilari Mäki-Opas1, Mari Hämäläinen1, Lauri J Moilanen1, Raisa Haavikko2, Tiina J Ahonen2, Sami Alakurtti2,3, Vânia M Moreira2,4, Katsuhiko Muraki5, Jari Yli-Kauhaluoma2, Eeva Moilanen1.
Abstract
TRPA1 is a nonselective cation channel, most famously expressed in nonmyelinated nociceptors. In addition to being an important chemical and mechanical pain sensor, TRPA1 has more recently appeared to have a role also in inflammation. Triterpenoids are natural products with anti-inflammatory and anticancer effects in experimental models. In this paper, 13 novel triterpenoids were created by synthetically modifying betulin, an abundant triterpenoid of the genus Betula L., and their TRPA1-modulating properties were examined. The Fluo 3-AM protocol was used in the initial screening, in which six of the 14 tested triterpenoids inhibited TRPA1 in a statistically significant manner. In subsequent whole-cell patch clamp recordings, the two most effective compounds (pyrazine-fused triterpenoids 8 and 9) displayed a reversible and dose- and voltage-dependent effect to block the TRPA1 ion channel at submicromolar concentrations. Interestingly, the TRPA1 blocking action was also evident in vivo, as compounds 8 and 9 both alleviated TRPA1 agonist-induced acute paw inflammation in mice. The results introduce betulin-derived pyrazine-fused triterpenoids as promising novel antagonists of TRPA1 that are potentially useful in treating diseases with a TRPA1-mediated adverse component.Entities:
Keywords: TRPA1; Transient receptor potential channels; inflammation; natural compounds; pain; triterpenoids
Mesh:
Substances:
Year: 2019 PMID: 31034197 DOI: 10.1021/acschemneuro.9b00083
Source DB: PubMed Journal: ACS Chem Neurosci ISSN: 1948-7193 Impact factor: 4.418